Browse Penn-owned technologies available for licensing.
A DNA vaccine targeting tumor endothelial marker 1 (TEM1) that allows to prevent and delay tumor progression without adverse effect on physiologic angiogenesis
Immunization against antigens specifically expressed on tumor vasculature is a very attractive immunotherapy options due to its ability to prevent solid tumor growth. TEM1 (also known as endosialin or CD248) is abundantly expressed on the vasculature of the majority of solid tumors making it a prime candidate for immunological targeting.
Dr. Coukos and his team at UPenn have developed a DNA vaccine encoding the full length TEM1 cDNA fused to the minimal domain of the tetanus toxoid (TT) adjuvant. Prophylactic vaccination completely protected immunized mice and significantly decreased tumor growth in tumor-bearing mice. Vaccine generated effective memory responses: mice challenged with tumor cells 6 months later remained tumor free.
Dr. George Coukos is the head of the department of oncology and director of the Ludwig Center for Cancer Research at the University of Lausanne (Switzerland) as well as Adjunct Professor of Obstetrics and Gynecology at Penn. Before he moved to Switzerland, Dr. Coukos has created the center for research on ovarian cancer at the University of Pennsylvania, where he worked for 22 years. Dr. Coukos is a world-renowned pioneer in cancer immunotherapy in the area of gynecological cancers, the author of more than 200 significant publications and the recipient of numerous scientific awards.
Stage of Development:
Facciponte, J.G.(2014) Tumor endothelial marker 1–specific DNA vaccination targets tumor vasculature.
J Clin Invest.
Docket # V4999